Repositioning Candidate Details
| Candidate ID: | R1465 |
| Source ID: | DB12831 |
| Source Type: | investigational |
| Compound Type: | small molecule |
| Compound Name: | Gabexate |
| Synonyms: | Gabexate |
| Molecular Formula: | C16H23N3O4 |
| SMILES: | CCOC(=O)C1=CC=C(OC(=O)CCCCCNC(N)=N)C=C1 |
| Structure: |
|
| DrugBank Description: | Gabexate is a synthetic serine protease inhibitor which has been used as an anticoagulant. It also known to decrease production of inflammatory cytokines. Gabexate has been investigated for use in cancer, ischemia-reperfusion injury, and pancreatitis. |
| CAS Number: | 39492-01-8 |
| Molecular Weight: | 321.377 |
| DrugBank Indication: | No approved indication. |
| DrugBank Pharmacology: | Gabexate bind and inhibits serine proteases in the coagulation cascade to prevent blood clotting. It also prevents proteolytic destruction of IkappaB resulting in suppression of the nuclear factor kappa-B signalling pathway. Ultimately this decreases the production of inflammatory cytokines such as tumor necrosis factor alpha which are produced as a result of NFkappaB activation. |
| DrugBank MoA: | Gabexate inhibits kallikrein, plasmin, and thrombin by binding to their active sites. The inhibition of these components of the coagulation cascade ultimately prevents the formation of fibrin which must be present and polymerized to form a clot. Gabexate decreases the production of inflammatory cytokines by attenuating NFkappaB and c-Jun N-terminal kinase (JNK) pathway activity. The exact mechanism for this is unknown but it is thought that gabexate prevents the proteolyytic destruction of IkappaB which deactivates NFkappaB and interferes with activator protein 1 binding to DNA. |
| Targets: | Plasma kallikrein inhibitor; Prothrombin inhibitor; Plasminogen inhibitor |
| Inclusion Criteria: | Therapeutic strategy associated |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs | |
|---|---|---|---|---|---|
| S05 | Anti-inflammatory | inflammatory | Bile acid; TNF-a inhibitor; Dual PPAR-α and -δ agonists; Toll-Like Receptor; (TLR)-4 antagonist; Caspase inhibitor; ASK-1 inhibitor | Ursodeoxycholic Acid; Pentoxifylline; Elafibranor; JKB-121; Emricasan; Selonsertib; | Details |
| Diseases ID | DO ID | Disease Name | Definition | Class |
|---|